Tofacitinib is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It belongs to the janus kinase (JAK) inhibitor class. It was discovered and developed by the National Institutes of Health and Pfizer. Tofacitinib is marketed as Xeljanz, Jaquinus amongst others. Pfizer in association with the National Institutes of Health developed this drug. In 2012, the FDA approved it for treating adults with moderately to severely active rheumatoid arthritis, who have are intolerant to or had an inadequate response from using methotrexate, for only the five-mg, twice-daily dose. It was done so as it was believed that a higher dose would not improve the risk-benefit ratio. However, by 2019, both in EU and US regulators recommended temporarily suspend prescribing of the 10 mg twice-daily dose, to those at high risk for pulmonary embolism in addition to USFDA warnings about the risk of blood clots. Warnings: Follow all Instructions on your medicine package and label. It is wise to tell your healthcare providers about all your medical allergies, illnesses, and all medicines you use. Before taking TOFACITINIB CITRATE: You should not use This medical drug if you are allergic to it This drug may also be used for purposes that may not have been listed in this medication guide. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified rosiglitazone manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.

The usage of this pharmaceutical substance: Read the Guide and, if available, the Patient Information Leaflet that will be provided by your pharmacist before you start taking TOFACITINIB CITRATE. If you have any questions related to this medical remedy, ask your pharmacist or doctor. Tofacitinib inhibits JAKs. By doing so, it prevents the phosphorylation and activation of STATs. Transcription of cells involved in hematopoiesis and immune cell function is adversely impacted by the JAK-STAT signaling pathway. Tofacitinib actions therapeutically inhibit the JAK-STAT pathway to decrease the inflammatory response. Tofacitinib is sold as a tablet of 5mg and 10mg prescription strength and as an extended- release tablet in 11mg and 22mg strengths. In the treatment of Rheumatoid Arthritis, the dose is 5 mg taken orally and 11mg is taking the extended-release tablet, taken once a day. In the treatment of active psoriatic arthritis patients, who are intolerant or did not have the desired response from using methotrexate or other DMARDs, are prescribed this medicine in combination with nonbiologic DMARDs. The dose set of such a combination is 5mg of the tablet or the 11 mg dose for the extended-release tablet and in the case of Ulcerative Colitis, the initial dose is set at 10 mg, a day taken orally for at least 8 weeks. After the treatment, the patients are evaluated and transitioned to maintenance therapy as per their need and recovery. If need, this course can be further continued for another 16 weeks. But if not benefit is achieved after 16 weeks, the user can stop using this medication.

It is obtainable in generic and brand versions. It is not covered by most Medicare and insurance plans, but pharmacy coupons can help balance the price. In the USA, the consumer pays an average retail price of $3,364.89, for a supply of 30 tablets of 10mg strength. In India, where it is made by generic drug makers, the price of 60 tablets of 5mg is around USD253. Prices may vary on the pharmacy you visit.

If you are looking to find TOFACITINIB CITRATE manufacturers and TOFACITINIB CITRATE suppliers, locate them quickly using Pipelinepharma's online marketplace. With this convenient B2B platform, you can order types of medications and quantities you require from companies that have passed our stringent vetting and quality control procedures. Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of TOFACITINIB CITRATE suppliers offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for this substance manufacturer and these substance suppliers that you are looking for. These also enable you to check the dossier status of this medicine, and the GMP approvals of the different variants of TOFACITINIB CITRATE. Also, each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where TOFACITINIB CITRATE is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and ordering process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers or suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are onboarded on the platform. This allows us to screen TOFACITINIB CITRATE manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.